Yi-Miao Guo, Yue Cui, Le Yang* and Xue-Qiang Wang*,
{"title":"含硼小分子抗癌药物的研究进展","authors":"Yi-Miao Guo, Yue Cui, Le Yang* and Xue-Qiang Wang*, ","doi":"10.1021/acsptsci.5c00238","DOIUrl":null,"url":null,"abstract":"<p >Small-molecule anticancer agents containing boron have attracted growing attention due to their unique chemical properties and promising anticancer activities. This review systematically summarizes recent advances in developing boron-based small-molecule agents, highlighting their molecular structures, mechanisms of action, and therapeutic applications. Specifically, it covers key categories such as boron neutron capture therapy (BNCT) agents, boron-based enzyme inhibitors, novel benzoxaborole derivatives, and boron-based reactive oxygen species (ROS)-targeting agents. The challenges associated with these boron-containing drugs, including limited tumor selectivity, suboptimal boron accumulation, and low bioavailability, are also highlighted. Additionally, it offers perspectives on future directions in the field, providing insights intended to guide ongoing research and development in boron-based anticancer therapies.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"8 8","pages":"2384–2400"},"PeriodicalIF":3.7000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recent Development of Boron-Containing Small-Molecule Anticancer Agents\",\"authors\":\"Yi-Miao Guo, Yue Cui, Le Yang* and Xue-Qiang Wang*, \",\"doi\":\"10.1021/acsptsci.5c00238\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Small-molecule anticancer agents containing boron have attracted growing attention due to their unique chemical properties and promising anticancer activities. This review systematically summarizes recent advances in developing boron-based small-molecule agents, highlighting their molecular structures, mechanisms of action, and therapeutic applications. Specifically, it covers key categories such as boron neutron capture therapy (BNCT) agents, boron-based enzyme inhibitors, novel benzoxaborole derivatives, and boron-based reactive oxygen species (ROS)-targeting agents. The challenges associated with these boron-containing drugs, including limited tumor selectivity, suboptimal boron accumulation, and low bioavailability, are also highlighted. Additionally, it offers perspectives on future directions in the field, providing insights intended to guide ongoing research and development in boron-based anticancer therapies.</p>\",\"PeriodicalId\":36426,\"journal\":{\"name\":\"ACS Pharmacology and Translational Science\",\"volume\":\"8 8\",\"pages\":\"2384–2400\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Pharmacology and Translational Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsptsci.5c00238\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsptsci.5c00238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Recent Development of Boron-Containing Small-Molecule Anticancer Agents
Small-molecule anticancer agents containing boron have attracted growing attention due to their unique chemical properties and promising anticancer activities. This review systematically summarizes recent advances in developing boron-based small-molecule agents, highlighting their molecular structures, mechanisms of action, and therapeutic applications. Specifically, it covers key categories such as boron neutron capture therapy (BNCT) agents, boron-based enzyme inhibitors, novel benzoxaborole derivatives, and boron-based reactive oxygen species (ROS)-targeting agents. The challenges associated with these boron-containing drugs, including limited tumor selectivity, suboptimal boron accumulation, and low bioavailability, are also highlighted. Additionally, it offers perspectives on future directions in the field, providing insights intended to guide ongoing research and development in boron-based anticancer therapies.
期刊介绍：
ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered.
ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition.
Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
